These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29522671)

  • 1. Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.
    Wang Y; Li L; Fan J; Dai Y; Jiang A; Geng M; Ai J; Duan W
    J Med Chem; 2018 Oct; 61(20):9085-9104. PubMed ID: 29522671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Optimization of a Novel 2
    Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
    J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
    Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
    Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
    Brameld KA; Owens TD; Verner E; Venetsanakos E; Bradshaw JM; Phan VT; Tam D; Leung K; Shu J; LaStant J; Loughhead DG; Ton T; Karr DE; Gerritsen ME; Goldstein DM; Funk JO
    J Med Chem; 2017 Aug; 60(15):6516-6527. PubMed ID: 28665128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A structure-guided approach to creating covalent FGFR inhibitors.
    Zhou W; Hur W; McDermott U; Dutt A; Xian W; Ficarro SB; Zhang J; Sharma SV; Brugge J; Meyerson M; Settleman J; Gray NS
    Chem Biol; 2010 Mar; 17(3):285-95. PubMed ID: 20338520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.
    Wei M; Peng X; Xing L; Dai Y; Huang R; Geng M; Zhang A; Ai J; Song Z
    Eur J Med Chem; 2018 Jun; 154():9-28. PubMed ID: 29775937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
    Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer molecules targeting fibroblast growth factor receptors.
    Liang G; Liu Z; Wu J; Cai Y; Li X
    Trends Pharmacol Sci; 2012 Oct; 33(10):531-41. PubMed ID: 22884522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis.
    Sahores A; May M; Sequeira GR; Fuentes C; Jacobsen B; Lanari C; Lamb CA
    Curr Cancer Drug Targets; 2018; 18(10):979-987. PubMed ID: 29237381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.
    Yan W; Wang X; Dai Y; Zhao B; Yang X; Fan J; Gao Y; Meng F; Wang Y; Luo C; Ai J; Geng M; Duan W
    J Med Chem; 2016 Jul; 59(14):6690-708. PubMed ID: 27348537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.
    Hu S; Liu Y; Ma J; Ding W; Chen H; Jiang H; Chen H; Wei S; Liu Y; Jin Q; Yuan H; Yan L
    J Med Chem; 2023 Jul; 66(13):8858-8875. PubMed ID: 37335602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
    Zhao G; Li WY; Chen D; Henry JR; Li HY; Chen Z; Zia-Ebrahimi M; Bloem L; Zhai Y; Huss K; Peng SB; McCann DJ
    Mol Cancer Ther; 2011 Nov; 10(11):2200-10. PubMed ID: 21900693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.
    Venetsanakos E; Brameld KA; Phan VT; Verner E; Owens TD; Xing Y; Tam D; LaStant J; Leung K; Karr DE; Hill RJ; Gerritsen ME; Goldstein DM; Funk JO; Bradshaw JM
    Mol Cancer Ther; 2017 Dec; 16(12):2668-2676. PubMed ID: 28978721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
    Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
    Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
    Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors.
    Deng W; Chen X; Liang H; Song X; Xiang S; Guo J; Tu Z; Zhou Y; Chen Y; Lu X
    Eur J Med Chem; 2024 Sep; 275():116558. PubMed ID: 38870833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
    Squires M; Ward G; Saxty G; Berdini V; Cleasby A; King P; Angibaud P; Perera T; Fazal L; Ross D; Jones CG; Madin A; Benning RK; Vickerstaffe E; O'Brien A; Frederickson M; Reader M; Hamlett C; Batey MA; Rich S; Carr M; Miller D; Feltell R; Thiru A; Bethell S; Devine LA; Graham BL; Pike A; Cosme J; Lewis EJ; Freyne E; Lyons J; Irving J; Murray C; Newell DR; Thompson NT
    Mol Cancer Ther; 2011 Sep; 10(9):1542-52. PubMed ID: 21764904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.